Allogene Therapeutics Inc

25 sept. 2026, 20:07 UTC

Allogene Therapeutics Inc shares fell sharply, marking their fourth consecutive day of losses, and remain significantly below the 20-day moving average.

24 sept. 2026, 23:40 UTC

Allogene Therapeutics Inc is advancing in after-market trading, rebounding sharply after a brief dip, despite remaining significantly below its 20-day moving average.

23 sept. 2026, 19:25 UTC

Allogene Therapeutics Inc shares fell sharply, pulling back from earlier gains and trading lower compared to Tuesday's close, remaining below its 20-day moving average.

22 sept. 2026, 23:10 UTC

Allogene Therapeutics Inc is higher in after-market trading, peaking above Tuesday's close, despite remaining below its 20-day moving average.

17 sept. 2026, 20:07 UTC

Allogene Therapeutics Inc is advancing, showing notable gains from Wednesday's close, despite remaining below its 20-day moving average.

16 sept. 2026, 23:01 UTC

Allogene Therapeutics Inc is moving higher in after-market hours, reflecting broader market trends following a 1.2% increase in U.S. retail sales for August.

10 sept. 2026, 20:07 UTC

Allogene Therapeutics Inc. shares are higher Thursday, following a cumulative gain since Wednesday's close, despite remaining below its 20-day moving average.

9 sept. 2026, 23:01 UTC

Allogene Therapeutics Inc shares are higher in after-market trading, reversing a three-session decline, though still below the 20-day moving average.

8 sept. 2026, 20:07 UTC

Allogene Therapeutics Inc shares are lower today amid broader market weakness, continuing a decline since Friday's close. No specific company news was identified.

3 sept. 2026, 19:36 UTC

Allogene Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains near the midpoint of its one-month trading range.

31 août 2026, 19:16 UTC

Allogene Therapeutics Inc shares are lower amid broader market declines following hawkish Fed comments. The company noted progress with cema-cel and FDA designations.

28 août 2026, 23:36 UTC

Allogene Therapeutics Inc shares are higher in after-market trading. No specific news was identified to explain this movement.

27 août 2026, 23:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock has gained over the past month.

26 août 2026, 19:56 UTC

Allogene Therapeutics Inc shares are lower during Wednesday's session, continuing a decline since Tuesday amid broader market concerns over persistent inflationary pressures.

25 août 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

24 août 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

21 août 2026, 19:56 UTC

Allogene Therapeutics Inc. shares are lower today, fluctuating within a routine range but remaining above their 20-day moving average.

20 août 2026, 22:16 UTC

Allogene Therapeutics Inc. shares are higher in after-market hours, despite earlier declines, amid rising U.S. Treasury yields and broader market pressure.

19 août 2026, 23:01 UTC

Allogene Therapeutics Inc. shares are lower in after-market hours, continuing a decline that began at the start of the session.

18 août 2026, 19:51 UTC

Allogene Therapeutics Inc. shares are trading lower amid broader market declines and rising Treasury yields, reflecting ongoing pressure in the biotechnology sector.

17 août 2026, 19:16 UTC

Allogene Therapeutics Inc shares rise following Citizens' Market Outperform rating and $6 price target. The broader Biotechnology sector also shows significant gains.

14 août 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. The stock remains above its 20-day moving average.

13 août 2026, 19:26 UTC

Allogene Therapeutics reported a net loss of $42.7 million, better than expectations, as shares trade lower amid concerns over a potential $500 million offering.

12 août 2026, 23:21 UTC

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

11 août 2026, 23:26 UTC

Allogene Therapeutics shares advanced during after-market hours, trading within a narrow range and remaining well above the 20-day moving average.

10 août 2026, 19:16 UTC

Allogene Therapeutics is trading higher, maintaining upward momentum despite a decline in U.S. stock futures following a labor market report.

7 août 2026, 19:16 UTC

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

6 août 2026, 19:46 UTC

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

5 août 2026, 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

3 août 2026, 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.